Phase II Combination Study
In the ongoing Phase II study, approximately 90 treatment-naive genotype 1 HCV patients have received ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin,
USP) for 12 weeks at dose levels of 200
mg bid or 400
mg bid, each with a loading dose of 800
mg bid on day one. After week 12, patients are to continue receiving SOC.